Attend

We are delighted to welcome you to our upcoming AI & DIGITAL INNOVATIONS World Congress 2026 Europe, hosted by FACILITATE LIVE. The Congress focuses on “Driving Smarter Science, Faster Trials and Stronger Value Through AI‐Enabled Innovation”.

The biopharmaceutical industry is entering a defining moment, one where scientific ambition, operational pressure and commercial expectations converge, and where artificial intelligence is rapidly becoming the most transformative force across the entire R&D and clinical value chain. What began as isolated pilots and exploratory proofs of concept has evolved into a new operating paradigm: AI as a strategic engine powering smarter science, faster development and stronger evidence. Organisations that embrace this shift are already seeing measurable gains in productivity, decision quality and competitive differentiation. Those that hesitate risk falling behind in an increasingly data‐driven, insight‐accelerated landscape.

The AI & DIGITAL INNOVATIONS CONGRESS convenes the leaders shaping that future. Senior executives, scientific innovators, clinical strategists, digital architects and commercial decision makers gather here to explore how intelligent technologies are redefining what is possible, from the earliest spark of discovery to the moment a therapy reaches patients and markets. The programme is designed not simply to showcase tools or trends, but to illuminate the structural changes underway across modern R&D and the strategic capabilities required to compete in an AI‐enabled world.

At the heart of this transformation is the rise of multimodal foundation models, generative design systems and predictive analytics that unlock deeper biological, chemical and clinical insight. These technologies are enabling organisations to interrogate complex data at unprecedented scale, design novel molecules and modalities with greater precision, and make high conviction decisions earlier in the development process. The implications are profound: accelerated timelines, reduced attrition, more resilient portfolios and assets with clearer commercial potential.

Equally significant is the operational revolution unfolding across clinical development. AI is reshaping trial design, feasibility modelling, patient stratification and site performance, while digital endpoints, sensors and remote monitoring are redefining how evidence is captured and validated. These innovations are not only improving scientific robustness—they are strengthening regulatory submissions, enhancing payer narratives and enabling more inclusive, patient‐centric trial experiences. The result is a clinical ecosystem that is faster, leaner and more capable of generating the high‐quality evidence required for successful launch and sustained market access.

Beyond science and operations, AI is also transforming how organisations think about strategy, investment and lifecycle value. Intelligent forecasting, continuous evidence generation and real‐time safety monitoring are creating new opportunities to optimise resources, reduce risk and extend the commercial impact of therapies long after approval. The convergence of scientific intelligence, operational excellence and evidence advantage is redefining what it means to lead in biopharma.

The AI & DIGITAL INNOVATIONS CONGRESS serves as a platform to understand these shifts, challenge assumptions and accelerate adoption. It is a meeting for candid discussion, cross‐functional collaboration and strategic alignment, bringing together the people and ideas that will shape the next decade of innovation. As AI continues to evolve, the organisations that harness its full potential will not only deliver better science and stronger evidence; they will define the future of therapeutic development and the competitive landscape of global healthcare.

We look forward to your participation!